ArticleWorld journal of gastroenterology2014
Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma.
Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Epithelioid Hemangioendothelioma: Treatment Landscape and Innovations for an Ultra-Rare Sarcoma.Current treatment options in oncology · 2025Review
- The challenges of hepatic epithelioid hemangioendothelioma: the diagnosis and current treatments of a problematic tumor.Orphanet journal of rare diseases · 2024Review
- Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.Theranostics · 2024Article
- Article
- Hepatic epithelioid hemangioendothelioma: Clinical characteristics, diagnosis, treatment, and prognosis.World journal of clinical cases · 2022Article
- Laparoscopic repeat liver resection for hepatic epithelioid hemangioendothelioma.Surgical case reports · 2020Article
- Primary lung neoplasms presenting as multiple synchronous lung nodules.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Hepatic epithelioid hemangioendothelioma: case series of a rare vascular tumor mimicking metastases.Diagnostic pathology · 2020Article
- Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?Therapeutics and clinical risk management · 2020Article
- [Research Progress of Pulmonary Epithelioid Hemangioendothelioma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- Malignant hepatic vascular tumors in adults: Characteristics, diagnostic difficulties and current management.World journal of clinical oncology · 2019Review
- Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment.Current treatment options in oncology · 2018Review
- Vascular tumours of the liver: a particular story.Translational gastroenterology and hepatology · 2018Review
- Review
- Pathological characteristics of liver biopsies in eight patients with hepatic epithelioid hemangioendothelioma.International journal of clinical and experimental pathology · 2015Article
- Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma.Clinical sarcoma research · 2015Article
- Therapy of Angiosarcoma with Thalidomide and Lenalidomide.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelioid hemangioendothelioma (EH) is a rare tumor arising from the vascular endothelial cells of soft tissue or visceral organs. The most common visceral site is the liver, where it is often involved in a multifocal manner known as hepatic EH (HEH). Surgical resection with curative intent represents the gold standard therapy. When surgery is not feasible, or in cases of metastatic disease, no standard medical treatment is currently indicated. In small series, drugs with anti-angiogenic activity (such as bevacizumab, sorafenib, thalidomide, and lenalidomide) have been proposed with promising results. We describe a 73-year-old man with multifocal non-resectable HEH treated with lenalidomide. Disease status was evaluated by abdominal ultrasound and magnetic resonance every four months. The patient was treated for a total of 39 mo with prolonged disease stabilization and, at the time of writing, is still under treatment with a good tolerance profile. During a short period of treatment discontinuation, the disease showed slight progression that immediately resolved after the reintroduction of lenalidomide. Lenalidomide may represent a valid treatment option for HEH due to its anti-angiogenic and antineoplastic activities. This preliminary result merits further study in a large series.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.